Related Experiment Video
Updated: Jun 16, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Slowing the growth of drug-resistant tumors
Yingyi Zhang1,2, Qianying Lu1,2
1School of Disaster and Emergency Medicine, Tianjin University, Tianjin, China.
Abstract:
Using drugs that inhibit enzymes called CDK4/6 and CDK2 extends the G1 phase of the cell cycle and helps to slow the growth of drug-resistant breast cancer.
Insights
New drugs targeting CDK4/6 and CDK2 enzymes slow the cell cycle, offering a promising strategy to inhibit the growth of drug-resistant breast cancer.
Area of Science:
- Oncology
- Cell Biology
- Pharmacology
Background:
- Drug-resistant breast cancer remains a significant clinical challenge.
- The cell cycle, particularly the G1 phase, is a critical regulator of cell proliferation.
- Cyclin-dependent kinases (CDKs) play a pivotal role in cell cycle progression.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
Related Concept Videos
Drugs that Stabilize Microtubules
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers